Vor Bio announced on July 21, 2025, the appointment of Alexander (Bo) Cumbo and Michel Detheux, Ph.D., to its Board of Directors, effective July 16, 2025. These appointments bring decades of experience in company building, corporate strategy, commercialization, and business development to Vor Bio.
Bo Cumbo currently serves as President and CEO of Solid Biosciences and previously held leadership roles at AavantiBio and Sarepta Therapeutics, where he played a central role in launching multiple rare disease therapies. Michel Detheux is President and CEO of iTeos Therapeutics, which he co-founded, leading it from discovery to late-stage clinical development and securing a $2 billion partnership with GSK.
The addition of these seasoned leaders is expected to provide invaluable insights as Vor Bio advances telitacicept through late-stage development and expands its long-term vision to bring transformative therapies to patients living with autoimmune disease. Their expertise is particularly relevant given the company's recent strategic pivot.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.